Filters
Use of phosphodiesterase 5 inhibitor (PDE5i) for erectile dysfunction (ED) or benign prostatic hyperplasia (BPD) does not seem to heighten the risk of ocular events in men, reveals a study.
Older adults with Alzheimer's disease who are receiving treatment with acetylcholinesterase inhibitors (AChEIs) appears to have a small reduction in the risk of age-related macular degeneration (AMD), as reported in a study.
Neutropenia following intra-arterial chemotherapy occurs more frequently than previously reported among children with retinoblastoma, with topotecan possibly linked to a risk increase, according to a study.
In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.
New drug applications approved by US FDA as of 01-15 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Wearing soft contact lenses with extended depth of focus reduces axial elongation and, in turn, delays the progression of myopia in children when compared with using distance single-vision spectacles, as shown in a study.
Thinner photoreceptor layers in the central macula appear indicative of genetic predisposition to age-related macular degeneration (AMD) in healthy Asians, as shown in a study from Singapore.
Use of immunosuppressants does not appear to increase the incidence of all-cause and cancer mortality in patients with noninfectious ocular inflammatory disease (OID) over a median follow-up of 10 years, a recent study has shown.
Treatment with placebo is successful in patients with open-angle glaucoma or ocular hypertension, achieving lower intraocular pressure (IOP), compared with untreated control participants, reports a recent study.
Combined trabeculectomy with trabeculectomy (CTT) confers benefits on patients with primary congenital glaucoma (PCG), suggests a study.
